伊索拉姆尼丁:回顾抗癌机制和纳米配方驱动的交付的最新发展
Juie Nahushkumar Rana1, Kainat Gul2, Sohail Mumtaz3
1Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.
International journal of molecular sciences
|August 14, 2025
概括
伊索拉姆尼丁是一种天然的黄胺,通过向细胞周期,细胞亡和转移等关键癌症机制,显示出显著的抗癌潜力. 这篇评论强调了其作为瘤学中安全有效的辅助疗法的承诺.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 黄类化合物,包括伊索拉姆尼丁,是具有已证明抗癌活性和低毒性的天然化合物.
- 伊索哈姆尼丁向多种癌症特征,使其成为一个重要的研究兴趣的化合物.
研究的目的:
- 综合审查异黄尼丁的抗癌机制.
- 探索异胺研究的最新进展,包括纳米配方和组合疗法.
主要方法:
- 对伊索拉姆尼丁抗癌作用的最新研究 (2022-2024) 的文献综述.
- 分析伊索拉姆尼丁对细胞循环调节,细胞亡,转移,血管生成,氧化应激和炎症的影响.
主要成果:
- 伊索拉姆尼丁抑制癌细胞增殖,并通过酶激活和线粒体功能障碍诱导亡.
- 它通过降低矩阵金属蛋白酶 (MMPs),血管内皮生长因子 (VEGF) 和上皮-介质酶过渡 (EMT) 标记物来抑制转移.
- 伊索拉姆尼丁具有抗氧化和抗炎性质,调节瘤微环境,并可能克服多药性耐药性.
结论:
- 伊索拉姆尼丁是一种多功能抗癌药物,在瘤学中具有作为辅助疗法的潜力.
- 纳米配方策略增强了其传递和生物可用性,改善了治疗结果.
- 对组合疗法和特定信号通路的进一步研究是有必要的.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K


